PROSTATE CANCER METASTATIC

This early-stage trial tests a new treatment made from a patient's own immune cells (TILs) for metastatic colorectal or prostate cancer. The goal is to see if repeated doses are safe and feasible in 12 participants. The therapy aims to help the immune system fight cancer, but ong…

This large Phase 3 trial is testing a new oral drug called opevesostat (MK-5684) against two standard drugs (abiraterone or enzalutamide) in men with metastatic castration-resistant prostate cancer that has worsened after prior hormone therapy and chemotherapy. The study aims to …

This Phase 3 trial tests whether adding darolutamide (Nubeqa) to standard hormone therapy (ADT) helps men with metastatic prostate cancer who are too frail for stronger treatments. About 300 participants will receive either darolutamide or a placebo, plus ADT. The goal is to see …

This phase 2 trial tests Enhertu, a targeted drug, in 60 men with HER2-positive prostate cancer that has spread and stopped responding to hormone therapy and newer drugs like abiraterone. Participants must have tried or refused chemotherapy. The study measures tumor shrinkage and…

This study tests whether adding targeted radiation to spots where prostate cancer has spread can help men whose cancer is already responding to hormone therapy. About 80 men with metastatic prostate cancer will be randomly assigned to get either standard care or standard care plu…

This study tests whether adding precise, high-dose radiation (SBRT) to standard hormone therapy can delay cancer progression in men with prostate cancer that has spread to 1-3 spots. About 118 participants will be randomly assigned to get SBRT plus standard care or standard care …

This study tests a new drug called OM-RCA-01, an antibody that blocks a protein called FGFR1 found on some cancer cells. About 58 adults with metastatic kidney, lung, prostate, breast, or head and neck cancers that express FGFR1 will receive the drug by IV every two weeks. The go…

This study tests whether a 16-week, culturally tailored exercise program (aerobic and resistance training) can lower heart disease risk in Black men with prostate cancer who are receiving hormone therapy (androgen deprivation therapy). The study will enroll 62 participants, who w…

This study follows 130 men with metastatic prostate cancer who are receiving standard treatment with abiraterone and prednisone. Researchers want to see if a person's race or ethnicity influences how well the drugs work, by measuring PSA levels and looking at genetic differences.…

This study tests whether a 12-week exercise program can reduce the number of cancer cells in the blood of men with advanced prostate cancer. Twenty men who are already on hormone therapy will participate. The goal is to see if exercise can help control the disease, not cure it.

This large Phase 3 trial tests whether adding targeted radiotherapy (SABR) or a radioactive drug (PSMA-Lutetium) to standard hormone therapy can slow cancer spread and improve survival in people with metastatic prostate cancer. About 3,360 participants across the UK will be rando…

This study tests a new radioactive tracer called [18F]FluorThanatrace (FTT) used with PET/CT scans to measure PARP-1 activity in men with metastatic prostate cancer. Up to 30 participants will have scans before and after starting a new therapy. The goal is to see if FTT can non-i…

This study explores whether a 7-day water-only fast or ketone supplements are safe and doable for men with prostate cancer. The idea is that fasting may change the body's metabolism and boost immune cells to better attack cancer. Researchers will track side effects and how many p…

This study aims to describe the characteristics of prostate cancer in Algeria, including patient demographics, symptoms, diagnosis methods, and treatments. Researchers will collect data from 2,000 men aged 19 and older with confirmed prostate cancer. The goal is to better underst…

This study is creating and testing a simple educational tool to help Black or African American men with metastatic prostate cancer understand genetic testing for their tumors. The goal is to make counseling fairer and easier to use. About 80 men will take part, first giving feedb…

This study looks at whether PSMA PET scans can predict how well advanced prostate cancer patients will respond to treatments like hormone therapy or chemotherapy. Researchers will scan 1300 patients before they start treatment and track their outcomes. The goal is to find imaging…

This study aims to see if a newer, dynamic type of PET scan can find prostate cancer that has spread better than the standard static scan. About 60 men with advanced prostate cancer that is no longer responding to hormone therapy will get both types of scans. The goal is to impro…

This study follows 120 men with advanced prostate cancer to see if markers in their blood can predict how well they respond to hormone therapy. Researchers will collect blood samples and compare markers between those who respond well and those who don't. The goal is to develop a …